Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201178 | 0.89 | CARM1 (0.39) | PYCR1HSP90AB1ALPL | |
| SCHEMBL16201413 | 0.88 | NMT1 (0.40) | CRHR1HSP90AB1ALDH1A1MAPT | |
| SCHEMBL16201404 | 0.88 | CRHR1 (0.44) | PYCR1CRHR1HSP90AB1 | |
| SCHEMBL16201360 | 0.88 | ALDH1A1 (0.36) | LMNAALDH1A1MAPT | |
| SCHEMBL16201377 | 0.88 | CRHR1 (0.38) | CRHR1ALDH1A1POLBMAPTGPR55 | |
| SCHEMBL16204226 | 0.86 | PRMT1 (0.41) | PYCR1HSP90AB1ALPL | |
| SCHEMBL16201405 | 0.86 | CRHR1 (0.47) | CRHR1ALDH1A1 | |
| SCHEMBL16201354 | 0.85 | HTR2A (0.34) | CRHR1ALDH1A1POLBMAPTGPR55 | |
| SCHEMBL16201393 | 0.84 | HRH3 (0.34) | HSP90AB1 | |
| SCHEMBL16201417 | 0.84 | MEN1 (0.39) | LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PYCR1 2429/4885CRHR1 3768/4885HSP90AB1 3485/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PYCR1 1488/4885CRHR1 3785/4885HSP90AB1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.